Please login to the form below

Not currently logged in
Email:
Password:

CRISPR Therapeutics appoints Dr Tony Coles

He takes up a seat on the Swiss biopharma's board of directors

CRISPR Tony ColesSwiss biopharma company CRISPR Therapeutics has appointed Dr Tony Coles to its board of directors.

He is currently founding investor, chairman and chief executive officer of Yumanity Therapeutics, a biotechnology company focused neurodegenerative diseases.

Rodger Novak, chief executive officer of CRISPR Therapeutics, said: “Dr Coles is a venerated leader in the biotech industry with a strong track record of success.

“The appointment of Dr Coles is in line with our effort to bring the best talent to CRISPR Therapeutics and rapidly become a leading biopharmaceutical company devoted to discovering and developing novel medicines for patients suffering from diseases with limited treatment options.”

Prior to founding Yumanity Dr Coles served as chairman and chief executive officer of Onyx Pharmaceuticals, which was acquired by Amgen in 2013 for $10.5bn.

He has also previously held executive and leadership positions at NPS Pharmaceuticals, Vertex Pharmaceuticals, Bristol-Myers Squibb and Merck & Co.

6th January 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics